OIA
NAVB

Optimum Investment Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Optimum Investment Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$5K Hold
150
– – ﹤0.01% 896
2014
Q4 		$6K Hold
150
– – ﹤0.01% 907
2014
Q3 		$4K Buy
+150
New +$3.97K ﹤0.01% 860

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Optimum Investment Advisors's NAVB Position: Q1 2015 in Review

Optimum Investment Advisors held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q1 2015 at 150 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Optimum Investment Advisors first reported a position in NAVB in Q3 2014 and has held it in 3 quarters since. The position peaked at $6K in Q4 2014. 82 funds tracked by Wall St. Rank hold NAVB as of Q1 2015.

  • Optimum Investment Advisors held 150 shares of Navidea Biopharmaceuticals Inc. worth $5K as of Q1 2015.
  • Optimum Investment Advisors left its Navidea Biopharmaceuticals Inc. share count unchanged in Q1 2015.
  • Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Optimum Investment Advisors's portfolio in Q1 2015, its #896 holding.
  • Optimum Investment Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2014 and has held it in 3 quarters since.
  • Optimum Investment Advisors's Navidea Biopharmaceuticals Inc. position peaked at $6K in Q4 2014.
  • 82 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2015.

Based on Optimum Investment Advisors's 13F filing for Q1 2015, filed 18 May 2015.